Nina combines an AI-enabled, Class II vaginal speculum with proprietary software and hardware as a redesigned to deliver a transformative solution for biodata collection and diagnostics for pharmaceutical companies.

Actual device is not pictured.

The Disease Burden

Women’s reproductive health remains critically underserved, with pharmaceutical innovation lagging behind due to insufficient biodata and limited understanding of population-specific factors.

Globally, reproductive health issues account for nearly 20% of the global disease burden among women of reproductive age, yet only 4% of healthcare R&D spending is directed toward women's health conditions.

The Problem

The development of effective pharmaceuticals and vaccines in women’s reproductive health is hindered by significant challenges, including a lack of precise biodata, limited understanding of population-specific access barriers, and inadequate diagnostic tools tailored for diverse patient populations.

Current data collection methods fail to capture the nuanced biological, environmental, and socioeconomic factors that influence women’s health outcomes, particularly for marginalized groups disproportionately impacted by conditions such as cervical cancer, endometriosis, and HPV-related diseases.

Nina is a Potential Solution

Nina would use AI and machine learning to process data, offering actionable insights on patient populations and disease trends.

Nina would facilitate the creation of vaccines by offering predictive insights into HPV progression and prevention strategies.

Nina is Comprised of Three Parts

  • Class II Medical Device

    Step 1: The AI-Powered Vaginal Speculum would be used for real-time biodata collection.

  • Cloud-Based Bioinformatics Bank

    Step 2: The Bioinformatics Bank receives and holds the data.

  • Proprietary Software

    Step 3: Our software would analyze and visualize the data providing actionable insights.

Nina as a Biodata Collection Tool and Diagnostic Device

Nina will redefine how pharmaceutical companies can access and leverage biodata in women’s reproductive health through a novel, AI-enabled class II speculum equipped with proprietary software, hardware, and an innovative design.

By directly addressing gaps in data collection and diagnostics, Nina would offer the following benefits to drug makers and pharmaceutical companies.